Loading...
(86/90)Y-Labeled Monoclonal Antibody Targeting Tissue Factor for Pancreatic Cancer Theranostics
Pancreatic cancer is highly aggressive, with a median survival time of less than 6 months and a 5-year overall survival rate of around 7%. The poor prognosis of PaCa is largely due to its advanced stage at diagnosis and the lack of efficient therapeutic options. Thus, the development of an efficient...
Saved in:
| Published in: | Mol Pharm |
|---|---|
| Main Authors: | , , , , , , , , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
2020
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7265990/ https://ncbi.nlm.nih.gov/pubmed/32202792 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/acs.molpharmaceut.0c00127 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|